Efficacy of albumin administration in hospitalised patients with community-acquired pneumonia: clinical trial, randomised prospective, multicenter (ALBUCAP) (Q3138734): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): Objective: Determine whether albumin administration can reduce time to clinical stability and improve other relevant evolutionary parameters in hospitalised hypoalbumine patients with community-acquired pneumonia (CAP). Design: Prospective, randomised (1:1) and multicenter clinical trial (ALBUCAP). Scope: Three hospitals in the Barcelona area Study subjects: Adult patients with CCN hospitalised through emergencies with serum albumin concentrat...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
Efficacy of albumin administration in hospitalised patients with community-acquired pneumonia: clinical trial, randomised prospective, multicenter (ALBUCAP) | |||
Revision as of 13:19, 12 October 2021
Project Q3138734 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy of albumin administration in hospitalised patients with community-acquired pneumonia: clinical trial, randomised prospective, multicenter (ALBUCAP) |
Project Q3138734 in Spain |
Statements
81,625.0 Euro
0 references
163,250.0 Euro
0 references
50.0 percent
0 references
1 January 2018
0 references
31 March 2021
0 references
INSTITUTO DE INVESTIGACION BIOMEDICA DE BELLVITGE
0 references
41°21'35.50"N, 2°5'59.24"E
0 references
08101
0 references
Objetivo: Determinar si la administración de albúmina puede reducir el tiempo hasta la estabilidad clínica y mejorar otros parámetros evolutivos relevantes en los pacientes hipoalbuminémicos hospitalizados con neumonía adquirida en la comunidad (NAC). Diseño: Ensayo clínico prospectivo, aleatorizado (1:1) y multicéntrico (ALBUCAP). Ámbito: Tres hospitales en el área de Barcelona Sujetos de estudio: Pacientes adultos con NAC hospitalizados a través de urgencias que tengan al ingreso una concentración de albúmina sérica = 30 g/L. El número de pacientes que serán incluidos es de 360. Intervención: Los pacientes serán asignados aleatoriamente a recibir por vía intravenosa, 100 ml de solución de albúmina al 20% (20 gramos) cada 12 horas durante un total de 4 días, o a recibir tratamiento estándar. Variable principal: Tiempo hasta la estabilidad clínica. Variables secundarias: Necesidad de ingreso en UCI y ventilación mecánica, duración del tratamiento antibiótico (intravenoso y total), eventos adversos, duración de la estancia hospitalaria, mortalidad por cualquier causa (a los 5 y a los 30 días) y necesidad de reingreso hospitalario (30 días). (Spanish)
0 references
Objective: Determine whether albumin administration can reduce time to clinical stability and improve other relevant evolutionary parameters in hospitalised hypoalbumine patients with community-acquired pneumonia (CAP). Design: Prospective, randomised (1:1) and multicenter clinical trial (ALBUCAP). Scope: Three hospitals in the Barcelona area Study subjects: Adult patients with CCN hospitalised through emergencies with serum albumin concentration = 30 g/L at admission. The number of patients to be included is 360. Intervention: Patients will be randomly assigned to receive 100 ml of 20 % (20 grams) albumin solution intravenously every 12 hours for a total of 4 days, or to receive standard treatment. Main variable: Time to clinical stability. Secondary variables: Need for admission to ICU and mechanical ventilation, duration of antibiotic treatment (intravenous and total), adverse events, length of hospital stay, all-cause mortality (at 5 and 30 days) and need for hospital readmission (30 days). (English)
12 October 2021
0 references
Hospitalet de Llobregat, L'
0 references
Identifiers
PI17_01332
0 references